Biologic Therapy
-
FDA Approves Exdensur (depemokimab) for Severe Asthma
GSK’s *Exdensur* (depemokimab-ulaa) has received FDA approval for severe eosinophilic asthma in adults and adolescents. This groundbreaking biologic offers an ultra-long-acting, twice-yearly dosing regimen, a first in its class, significantly reducing asthma exacerbations based on SWIFT-1 and SWIFT-2 trials. It addresses a critical unmet need, potentially transforming patient care with improved adherence and reduced healthcare burden.
